What's New, Updates and Changes to the Guidance

This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Where applicable, all regimens have been reordered by pan-genotypic activity, level of evidence, and alphabetically. Updated references have been provided throughout the guidance where appropriate. Sections of the guidance where key updates occurred are listed below.

Initial Treatment of Adults with HCV Infection & Patients With HIV/HCV Coinfection

  • Removal of HIV as a contraindication to the simplified treatment approach.
  • Addition of TDF containing regimen with eGFR <60 ml/min as an exclusion in HIV coinfection to simplified treatment approach.
  • Removal of 12-week glecaprevir/pibrentasvir recommendation for HIV with cirrhosis.
  • Re-ordering of all regimens by pan-genotypic activity, level of evidence, and alphabetically.

Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy

  • Data about the minimal monitoring HCV study (MINMON) included to provide evidence to support the simplified HCV treatment monitoring algorithm.


  • Addition of recommendations for sofosbuvir/velpatasvir as a treatment for DAA experienced children and adults.
Monday, October 24, 2022